...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

ya im not to excited about seeing great science NR's for years to come all the while looking at a 1 to 10 cent share price.

I'm here to make some money & not look at another decade of research while buddy fills his pockets & tells me how fricking excited & hard working he is - save that carny act for your wine parties.

Share
New Message
Please login to post a reply